Bristol-Myers Squibb
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - General
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Bristol-Myers Squibb (BMY) | 120.19B | 13.04 | 5.14 | 4.29% |
| Eli Lilly and Co (LLY) | 1.27T | 43.72 | 31.47 | 0.50% |
| Johnson & Johnson (JNJ) | 651.11B | 41.10 | 7.99 | 1.95% |
| AbbVie (ABBV) | 505.89B | 49.26 | -110.37 | 2.39% |
| Merck & Co (MRK) | 329.65B | 135.07 | 7.34 | 2.54% |
| Novartis AG (NVS) | 284.18B | 28.72 | 7.63 | 3.15% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 19.0% below Morningstar's fair value estimate.
Analyst note
Bristol saw 7% revenue growth and a 17% non-GAAP EPS decline (including acquisition charges) in the third quarter. Management raised 2026 revenue guidance to $50 billion at the midpoint (up from $49.5 billion) and lowered non-GAAP EPS guidance to $6.45 at the midpoint (to factor in acquisitions).
Why it matters: Bristol's shares were relatively flat on Oct. 29, and financial performance in the quarter was in line with our expectations. We think investors are awaiting additional data to determine how well Bristol can fight upcoming patent cliffs for oncology drug Opdivo and cardiovascular drug Eliquis. Double-digit sales growth of Eliquis and newer hematology, oncology, and cardiovascular therapies offset continued declines for the Celgene portfolio, including multiple myeloma drugs Revlimid and Pomalyst.
The bottom line: We're maintaining our $70 fair value estimate for wide-moat Bristol, after slightly lowering our sales assumptions for drugs with weaker growth prospects (Sotyktu in psoriasis and Krazati in cancer) but raising our estimates for pipeline drugs admilparant and iza-bren. Positive data for novel drug candidate admilparant in idiopathic pulmonary fibrosis bodes well for upcoming data in early 2027 in progressive pulmonary fibrosis, expanding the market opportunity for this underappreciated asset. The oncology pipeline is also expanding into broader indications, and we're more positive on the potential for iza-bren (lung and breast cancer) and pumitamig (lung cancer) to drive sales growth beyond key patent cliffs.
Coming up: Data for cardiovascular drug candidate milvexian (in secondary stroke prevention by the end of 2026 and atrial fibrillation in the first quarter of 2027) stands as the most important catalyst for Bristol's shares. Success in both trials would be upside to our current forecast.
BLANK PAGEIn multiple myeloma, Bristol's recent Zenbexus (iberdomide) approval and likely upcoming approval for mezigdomide and arlo-cel in 2027 are likely to tap into key niches of the market, like community-based physician practices and patients who have relapsed after BCMA-targeted therapy.
Sales of schizophrenia drug Cobenfy are growing slowly and likely need a combination of additional marketing (to educate physicians on dosing schedules and gastrointestinal side effects) and clinical data (in new markets like Alzheimer's psychosis) to accelerate.
For more information on Bristol's portfolio and pipeline, please see our recent in-depth Observer, "Biopharma Product Pipelines Rise to Meet Steeper Patent Cliffs."
Fair value
We're maintaining our fair value estimate at $70 per share.
We project compound annual sales declines of nearly 6% over the five years ending in 2030 as newer core drugs like cardiovascular drug Camzyos, cell therapy Breyanzi, anemia drug Reblozyl, and schizophrenia drug Cobenfy partially offset patent pressures, including the recent loss of exclusivity for cancer drugs Revlimid and Pomalyst and upcoming losses for cardiovascular drug Eliquis (by 2028), and cancer drug Opdivo (2028).
We believe the Celgene acquisition created value for Bristol, even though Revlimid and Pomalyst now create growth headwinds as generics enter the market. The acquisition gives Bristol a strong pipeline focused on oncology, including cell therapy Breyanzi and next-generation multiple myeloma therapies in testing. The therapeutic area overlap and $2.5 billion in annual cost synergies (the majority from selling, general, and administrative expense and likely commercial overlap and overhead) made the deal a strategically smart one, in our eyes.
We project that Opdivo will reach peak global sales of more than $11 billion. While sales should begin to see double-digit declines in 2029, we expect some mitigation of declines from sales of combination drug Opdualag ($2 billion-$3 billion in peak sales assumed) and next-generation immunotherapy pumitamig ($3 billion in probability-adjusted sales, accounting for Bristol's share of profits). We assume that Cobenfy sales could grow to $5 billion annually by 2034, with upside to our estimates if additional trials read out positively over the next couple of years.
Longer term, Bristol is developing a strong pipeline to mitigate the patent losses on its top drugs. The pipeline's focus on immunology, oncology, rare diseases, cardiology, and neurology should increase the probability of development success, given the higher level of unmet medical need in these areas.
Under our updated discount-rate framework, we've raised our Bristol WACC estimate to 7.1% from 7.0%. Our beta of 0.6 reflects our view of both biopharma's defensive nature and Bristol's own fundamentals and market returns. The change does not reflect a new view of the business, but a more granular expression of our existing risk assessment.
Economic moat
Based on a wide lineup of patent-protected drugs, an entrenched salesforce, and economies of scale, Bristol holds a wide economic moat. The patent protection allows the firm to price its drugs at levels that translate into superior returns on invested capital compared with its cost (particularly in cancer drugs, an area of focus for Bristol). The patents also provide Bristol with ample time to bring forward the next generation of new drugs. Several of Bristol's currently marketed drugs are biologics, which create additional hurdles for generic firms as the cost of developing and marketing biosimilars is much higher than for typical generic small molecules. Further, because many small drug firms lack a distribution channel, Bristol's entrenched salesforce enables the company to partner with these smaller drug companies to gain access to externally created drugs, augmenting its internal drug-development efforts. Additionally, Bristol's sheer size generates the strong and stable cash flows required to fund the clinical trials needed to bring each new drug to the market.
Bristol faces a significant patent cliff by 2028 for its mature portfolio, including cancer drugs Revlimid and Pomalyst and cardiovascular drug Eliquis. In addition, cancer drug Opdivo (21% of 2025 sales) will see US patents expire on its older intravenous formulation in 2028 and potential Medicare negotiation in 2029, although a newer subcutaneous version (Opdivo Qvantig), combination therapies (Opdualag), and novel cancer immunotherapies (phase 3 drug candidate pumitamig, from a collaboration with BioNTech) should all help mitigate Opdivo patent loss pressure.
We think newer therapies like anemia drug Reblozyl, cancer therapy Breyanzi, cardiovascular drug Camzyos, and neuroscience drug Cobenfy will help soften the impact of Bristol's patent cliff. With probability-weighted sales for the most advanced drug candidates, we forecast adjusted ROICs over the next 10 years in the low teens, still well above its 7% cost of capital. We also think Bristol's pipeline is poised to generate significant data in 2026 that could raise our assumed probabilities of approval and help restore the firm's historically strong ROICs.
We think the company does face environmental, social, and governance risks, particularly related to potential US drug price-related policy reform to increase access by lowering drug prices (close to 70% of sales are generated in the US). Ongoing product governance issues, including litigation related to side effects and patents, also weigh on the company. While we have factored these threats into our analysis, we don't see them as overly material to our moat rating.
Bull case
Bristol is launching innovative drugs in cardiology and neurology, which should have strong sales trajectories, given the high unmet medical need.
We forecast oncology drug Opdivo will see annual peak sales of more than $11 billion, helping to fuel development costs for the next generation of drugs.
The majority of Bristol's late-stage pipeline focuses on rare diseases, immunology, and cancer, where drug firms hold strong pricing power and the Food and Drug Administration aggressively approves new therapies.
Bear case
The acquisition of Celgene came shortly before the start of generic competition for that firm's cancer drug Revlimid in 2022, setting up a major growth obstacle over several years, given the planned staggered generic entry.
Bristol faces one of the larger patent cliffs by 2028, when cancer drug Opdivo and cardiovascular drug Eliquis likely face heavy generic competition.
The Celgene acquisition added significant debt that could become challenging to repay if competition strengthens against key drugs or pricing pressures intensify in the US.
By Karen Andersen, CFA
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Bristol-Myers Squibb discussion 0 comments